MCID: SKN020
MIFTS: 33

Skin Papilloma

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Papilloma

MalaCards integrated aliases for Skin Papilloma:

Name: Skin Papilloma 12 15 73
Cutaneous Papilloma 12
Papilloma of Skin 12
Papilloma Skin 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3178
NCIt 50 C4614
UMLS 73 C0347390

Summaries for Skin Papilloma

MalaCards based summary : Skin Papilloma, also known as cutaneous papilloma, is related to squamous cell papilloma of skin and papilloma. An important gene associated with Skin Papilloma is SP8 (Sp8 Transcription Factor), and among its related pathways/superpathways is Influenza A. The drugs Miconazole and Salicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and liver, and related phenotypes are cellular and growth/size/body region

Related Diseases for Skin Papilloma

Diseases related to Skin Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma of skin 11.0
2 papilloma 10.4
3 adenoma 9.8
4 breast adenoma 9.6
5 lung adenoma 9.6
6 endotheliitis 9.6

Graphical network of the top 20 diseases related to Skin Papilloma:



Diseases related to Skin Papilloma

Symptoms & Phenotypes for Skin Papilloma

MGI Mouse Phenotypes related to Skin Papilloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.7 CCDC39 EIF2AK4 IRF9 MAP2K2 ODC1 SMARCAL1
2 growth/size/body region MP:0005378 9.43 CCDC39 EIF2AK4 MAP2K2 ODC1 SMARCAL1 SP8
3 skeleton MP:0005390 9.02 CCDC39 IRF9 MAP2K2 SMARCAL1 SP8

Drugs & Therapeutics for Skin Papilloma

Drugs for Skin Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 22916-47-8 4189
2
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 69-72-7 338
3
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
4
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
5
Fluorouracil Approved Phase 4 51-21-8 3385
6 Analgesics Phase 4,Phase 2,Phase 3
7 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
8 Antifungal Agents Phase 4,Phase 2,Phase 3
9 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
12 Antirheumatic Agents Phase 4,Phase 2,Phase 3
13 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
14 Dermatologic Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Keratolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Salicylates Phase 4,Phase 2,Phase 3
18 Liver Extracts Phase 4,Phase 3
19 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antibodies Phase 4,Phase 3,Phase 1
25 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1
26 Calcineurin Inhibitors Phase 4
27 Cyclosporins Phase 4
28 Immunoglobulins Phase 4,Phase 3,Phase 1
29 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
30 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
31 Antimetabolites Phase 4,Phase 1,Phase 2
32 Antimetabolites, Antineoplastic Phase 4,Phase 1,Phase 2
33 pyruvate Nutraceutical Phase 4,Phase 2,Phase 3
34
Catechin Nutraceutical Phase 4,Phase 1 154-23-4 9064
35
Epicatechin Investigational, Nutraceutical Phase 4,Phase 1 490-46-0 72276
36 Tea Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
37
Ethanol Approved Phase 2, Phase 3,Not Applicable 64-17-5 702
38
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
39
Aminolevulinic acid Approved Phase 3 106-60-5 137
40
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
41
Pancrelipase Approved, Investigational Phase 3 53608-75-6
42
Benzocaine Approved, Investigational Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
43
Furosemide Approved, Vet_approved Phase 3,Phase 2 54-31-9 3440
44
Lenograstim Approved, Investigational Phase 3 135968-09-1
45
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
46 tannic acid Approved, Nutraceutical Phase 3,Not Applicable
47
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
48 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
49 Alkylating Agents Phase 3
50 Antineoplastic Agents, Alkylating Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Unknown status NCT01712295 Phase 4 17% Salicylate with ethyl pyruvate;Salicylates
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Completed NCT00761371 Phase 4 Imiquimod 5% cream
4 Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
5 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
6 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study Completed NCT02622568 Phase 4 Veregen only
7 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
8 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
9 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
10 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
11 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
12 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
13 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
14 A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
15 Comparison of Five Treatments in Patients With Plantar Warts Terminated NCT01059110 Phase 4 Salicylate ointment;Imiquimod;5-Fluoro-Uracil;Cryotherapy
16 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
17 Efficacy of Laser Versus Cryotherapy in the Treatment of Warts Unknown status NCT01808443 Phase 3
18 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
19 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
20 Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
21 Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial Completed NCT01783353 Phase 2, Phase 3
22 Low Dose Cyclophosphamide Treats Genital Warts Completed NCT00999986 Phase 3 cyclophosphamide
23 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
24 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
25 Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
26 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
27 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
28 Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) Completed NCT00517309 Phase 3
29 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
30 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
31 Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) Completed NCT00092495 Phase 3
32 Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) Completed NCT00092482 Phase 3
33 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
34 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
35 Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients Completed NCT00677677 Phase 3
36 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
37 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
38 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
39 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
40 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
41 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
42 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
43 Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT01412944 Phase 3 secukinumab 150mg;secukinumab 10mg/kg i.v. regimen
44 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) Completed NCT01952015 Phase 3
45 Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts Recruiting NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
46 Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response Recruiting NCT03296397 Phase 3
47 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Recruiting NCT02231879 Phase 3 Plerixafor;G-CSF
48 A Trial of X4P-001 in Patients With WHIM Syndrome Recruiting NCT03005327 Phase 2, Phase 3 X4P-001;Placebo
49 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients Recruiting NCT03525210 Phase 3
50 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod

Search NIH Clinical Center for Skin Papilloma

Genetic Tests for Skin Papilloma

Anatomical Context for Skin Papilloma

MalaCards organs/tissues related to Skin Papilloma:

41
Skin, Testes, Liver, Kidney, Bone, T Cells, Breast

Publications for Skin Papilloma

Articles related to Skin Papilloma:

(show all 40)
# Title Authors Year
1
Poly-MVA attenuates 7,12- dimethylbenz[a]anthracene initiated and croton oil promoted skin papilloma formation on mice skin. ( 28976135 )
2017
2
Deletion of epidermal Rac1 inhibits HPV-8 induced skin papilloma formation and facilitates HPV-8- and UV-light induced skin carcinogenesis. ( 27506937 )
2016
3
Attenuation of DMBA/croton oil induced mouse skin papilloma by Apodytes dimidiata mediated by its antioxidant and antimutagenic potential. ( 26878464 )
2016
4
Activation of MEK2 is sufficient to induce skin papilloma formation in transgenic zebrafish. ( 26572230 )
2015
5
The loss of Tm7sf gene accelerates skin papilloma formation in mice. ( 25804527 )
2015
6
Photodynamic therapy using a novel photosensitizer, TONS501, is similarly effective to ALA and EC036 photodynamic therapy on DMBA-and TPA-induced mouse skin papilloma. ( 22464765 )
2012
7
Flower-deficient mice have reduced susceptibility to skin papilloma formation. ( 22362363 )
2012
8
Phellinus rimosus (Berk.) pilat attenuates 7,12-dimethylbenz[a] anthracene induced and croton oil promoted skin papilloma formation in mice. ( 22070052 )
2011
9
Modulation of Signal Proteins: A Plausible Mechanism to Explain How a Potentized Drug Secale Cor 30C Diluted beyond Avogadro's Limit Combats Skin Papilloma in Mice. ( 19617203 )
2011
10
Bilharzia of the breast masquerading as a breast skin papilloma in a pregnant woman. ( 22353277 )
2011
11
Increased skin papilloma formation in mice lacking glutathione transferase GSTP. ( 21975931 )
2011
12
Anti-oncogenic potentials of a plant coumarin (7-hydroxy-6-methoxy coumarin) against 7,12-dimethylbenz [a] anthracene-induced skin papilloma in mice: the possible role of several key signal proteins. ( 20619141 )
2010
13
Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. ( 20080939 )
2010
14
The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. ( 19587094 )
2009
15
Congenital mucus retention cyst of penis presenting as skin papilloma. ( 17320684 )
2007
16
Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against DMBA-induced skin papilloma. ( 17622315 )
2007
17
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. ( 17909021 )
2007
18
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. ( 16624193 )
2006
19
Identification of genes and gene ontology processes critical to skin papilloma development in Tg.AC transgenic mice. ( 16329151 )
2006
20
Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. ( 15215482 )
2004
21
Control of intracellular movement of connexins by E-cadherin in murine skin papilloma cells. ( 11640887 )
2001
22
Prevention of carcinogen-induced mouse skin papilloma by whole fruit aqueous extract of Momordica charantia. ( 10958332 )
2000
23
Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg.AC transgenic mice and FVB/N mice. ( 9647747 )
1998
24
Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion. ( 9537245 )
1998
25
Mathematical modeling of skin papilloma data in SENCAR mice. ( 9439737 )
1997
26
Suppression of mouse skin papilloma by canthaxanthin and beta-carotene in vivo: possibility of the regression of tumorigenesis by carotenoids without conversion to retinoic acid. ( 8875557 )
1996
27
Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue. ( 8640752 )
1996
28
Expression of protein kinase C isoforms in skin papilloma and carcinoma of mice. ( 8062222 )
1994
29
Mouse skin papilloma formation by chronic dermal application of 7,12-dimethylbenz[a]anthracene is not reduced by diet restriction. ( 8293538 )
1994
30
Effect of excess dietary retinoic acid on skin papilloma and carcinoma formation induced by a complete carcinogenesis protocol in female Sencar mice. ( 8180970 )
1994
31
Effects of dietary retinoic acid on skin papilloma and carcinoma formation in female SENCAR mice. ( 8453733 )
1993
32
Dietary retinoids are essential for skin papilloma formation induced by either the two-stage or the complete tumorigenesis model in female SENCAR mice. ( 1451104 )
1992
33
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin papilloma by saponins. ( 1846234 )
1991
34
Inhibition of 7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs. ( 2529051 )
1989
35
A combined carcinogen bioassay utilizing both the lung adenoma and skin papilloma protocols. ( 3780626 )
1986
36
Dehydroepiandrosterone (DHEA) and 3 beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice. ( 6231135 )
1984
37
Inhibition by quercetin of the promoting effect of teleocidin on skin papilloma formation in mice initiated with 7,12-dimethylbenz[a]anthracene. ( 6428958 )
1984
38
Further studies of eel virus (Berlin) isolated from the blood of eels (Anguilla anguilla) with skin papilloma. ( 981684 )
1976
39
Suspicious influence of thymectomy on skin papilloma induction. ( 5781976 )
1969
40
Close-packed array of virus-like particles within cells of a human skin papilloma. ( 13121031 )
1953

Variations for Skin Papilloma

Expression for Skin Papilloma

Search GEO for disease gene expression data for Skin Papilloma.

Pathways for Skin Papilloma

Pathways related to Skin Papilloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.49 EIF2AK4 IRF9 MAP2K2

GO Terms for Skin Papilloma

Sources for Skin Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....